.jpeg)
2026-07-23 02:50:52
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor for ALK-positive advanced NSCLC with potent ALK inhibition and superior CNS penetration. This article covers its mechanism of action, therapeutic advantages, efficacy factors, and adverse effect management.
2026-07-23 02:43:41
In July 2026, the FDA approved subcutaneous isatuximab (Sarclisa) for multiple myeloma across three indications spanning newly diagnosed to relapsed/refractory disease. This article reviews pivotal trial data, recommended dosing, and key safety warnings.
2026-07-23 02:29:04
Pemigatinib is an FGFR inhibitor for FGFR2 fusion/rearrangement-positive cholangiocarcinoma. This article covers common adverse effects (hyperphosphatemia, alopecia, stomatitis), ophthalmologic monitoring requirements, and dose modification strategies for safe long-term treatment.
2026-07-23 02:21:07
Selpercatinib is a selective RET kinase inhibitor for RET fusion-positive NSCLC and RET-mutant medullary thyroid carcinoma. This guide addresses meal timing, twice-daily dosing, missed dose management, and key monitoring considerations during treatment.
2026-07-23 02:11:21
Mitotane is the cornerstone drug for adrenocortical carcinoma (ACC) treatment. This article covers initial dosing, target plasma concentration range (14–20 mg/L), monitoring frequency, and adverse effect management for safe and effective therapy.
2026-07-22 04:17:54
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates endogenous erythropoietin production by mimicking the physiological response to hypoxia, offering an injection-free treatment option for patients with chronic kidney disease-related anemia. This article systematically reviews its mechanism of action, clinical efficacy, and safety profile.
2026-07-22 04:06:31
Ponatinib and olverembatinib are both third-generation BCR-ABL tyrosine kinase inhibitors effective against the T315I gatekeeper mutation. This article provides a systematic comparison across target coverage, clinical efficacy, cardiovascular safety, and dosing strategies to inform treatment decisions.
2026-07-21 07:22:56
A balanced review of leflunomide-related eye symptoms, incidence, monitoring recommendations, and management strategies for rheumatoid arthritis patients.
2026-07-21 07:17:20
A structured overview of progression criteria, molecular profiling, and sequential treatment strategies following resistance to garsorasib in advanced NSCLC.
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
2026-07-20 07:25:47
Avatrombopag is an oral thrombopoietin receptor agonist indicated for chronic liver disease-associated thrombocytopenia and chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older, promoting platelet production via bone marrow stimulation.
2026-07-20 07:22:46
Capivasertib is an oral AKT inhibitor used to treat breast cancer and prostate cancer. This article compares the original brand and generic versions from Laos, highlighting differences in price, composition, and considerations for selection.
